TickerFacts.

UroGen Pharma Ltd. (URGN): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$162.73M
Year ended 2025-12-31
-$159.13M
Trailing 12 months to 2026-06-30
$3.49M2015-12-31: -$7.48M2016-12-31: $3.49M2017-12-31: -$9.84M2018-12-31: -$37.89M2019-12-31: -$71.34M2020-12-31: -$107.10M2021-12-31: -$85.64M2022-12-31: -$87.81M2023-12-31: -$76.57M2024-12-31: -$97.06M2025-12-31: -$162.73M-$162.73M
2015-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$162.73Mn/m2026-03-02, From 2025-01-01
2024-12-31-$97.06Mn/m2026-03-02, From 2024-01-01
2023-12-31-$76.57Mn/m2025-03-10, From 2023-01-01
2022-12-31-$87.81Mn/m2024-03-14, From 2022-01-01
2021-12-31-$85.64Mn/m2023-03-24, From 2021-01-01
2020-12-31-$107.10Mn/m2022-03-21, From 2020-01-01
2019-12-31-$71.34Mn/m2021-03-18, From 2019-01-01
2018-12-31-$37.89Mn/m2020-03-02, From 2018-01-01
2017-12-31-$9.84Mn/m2020-03-02, From 2017-01-01
2016-12-31$3.49Mn/m2019-02-28, From 2016-01-01
2015-12-31-$7.48Mn/a2018-03-15, From 2015-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
UroGen Pharma Ltd. (URGN)2025-12-31-$162.73Mn/m
Theravance Biopharma, Inc. (TBPH)2025-12-31$238.50Mn/m
Zevra Therapeutics, Inc. (ZVRA)2025-12-31-$2.43Mn/m
Zymeworks Inc. (ZYME)2025-12-31-$34.53Mn/m
Gyre Therapeutics, Inc. (GYRE)2025-12-31-$180.0Kn/m
Xencor Inc (XNCR)2025-12-31-$138.27Mn/m
Lifecore Biomedical, Inc. (LFCR)2025-05-25-$13.62Mn/m
Cytokinetics Inc (CYTK)2025-12-31-$534.82Mn/m
Standard Biotools Inc. (LAB)2025-12-31-$82.65Mn/m

Compare URGN, TBPH, ZVRA, ZYME side by side · Screen every company in Pharmaceutical Preparations ↗